Phenominer Database Results (9 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.9 cm3 0.16 0.55 magnetic resonance imaging liver 0.0 24 days portal vein occlusion group POD17 portal vein occlusion group POD17 110824 3191
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 58.6 % 8.2 28.41 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days portal vein occlusion group POD30 portal vein occlusion group POD30 110820 3191
BDIX/OrlCrl post excision/regeneration liver volume to original liver volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 220.0 % 25.3 87.64 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110816 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.2 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 31 days portal vein occlusion group POD24 portal vein occlusion group POD24 110989 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.09 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 110997 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 725.0 % 151.0 523.08 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 111002 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.79 cm3 0.15 0.52 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 110993 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2839.0 % 502.0 1738.98 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 111005 3191
BDIX/OrlCrl liver volume after excision and regeneration DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 8.1 cm3 1.07 3.71 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110814 3191